Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2023-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：百济神州有限公司截至2023年6月30日止六个月中期业绩公告
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report for BeiGene, Ltd. covering the six months ended June 30, 2023. It includes unaudited condensed consolidated financial statements such as income statements, balance sheets, cash flow statements, and statements of shareholders' equity, along with notes on accounting policies, business description, and prior period financial statement revisions. The report references US GAAP and compliance with SEC Form 10-Q guidelines and Hong Kong Stock Exchange listing rules. The length is substantial (15,000 characters), and it contains actual financial data and analysis for a half-year period, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
百济神州有限公司关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2023 half-year performance explanation meeting (业绩说明会) for investors, to be held on August 30, 2023. It mentions that the company will release its 2023 half-year report on that date and that the meeting will discuss the half-year operating results and financial indicators. The document does not contain the actual half-year financial report or detailed financial data but rather informs investors about the upcoming event and how to participate. The document length is short (1582 characters) and serves as a notice for an investor presentation event rather than the report itself. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, rather than the actual Interim/Quarterly Report (IR) or an Earnings Release (ER).
2023-08-22 Chinese
港股公告：审计委员会会议日期
Report Publication Announcement Classification · 95% confidence The document is a public announcement from BeiGene, Ltd. regarding the date of the Audit Committee meeting scheduled for August 25, 2023, to review and approve the company's interim results for the six months ended June 30, 2023. It references prior announcements of quarterly and half-year results filed with the U.S. SEC on Form 10-Q and mentions compliance with the Hong Kong Stock Exchange listing rules. The document does not contain the actual interim financial statements or detailed financial data but rather announces the meeting date and the intention to approve the interim results. The document length is short (890 characters), and it serves as a notice rather than the report itself. Therefore, according to the MENU VS MEAL RULE, this is a Report Publication Announcement (RPA) or a Regulatory Filing (RNS). Since it is a specific announcement about the Audit Committee meeting date and not a general regulatory filing, the best fit is Report Publication Announcement (RPA).
2023-08-14 Chinese
港股公告：授出购股权及受限制股份单位
Remuneration Information Classification · 95% confidence The document is a formal announcement from BeiGene, Ltd. regarding the grant of share options and restricted share units under the 2016 Option and Incentive Plan. It details the number of shares/options granted, exercise prices, vesting schedules, and related terms. The document references compliance with listing rules and provides definitions related to the share plan. There is no financial performance data, earnings information, or management discussion of results. The content focuses on equity compensation awards to employees, which is a form of director or management remuneration information. However, since it is an announcement of the grant of share options and restricted shares rather than a detailed remuneration report, it fits best under the category of Director's Dealing or Remuneration Information. It is not a Director's Dealing report (which involves personal share transactions by directors), but rather a remuneration-related announcement. Given the specificity of the content about share-based compensation grants, the best fitting category is Remuneration Information (DEF 14A). The document length is 3512 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is DEF 14A with high confidence.
2023-08-09 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 100% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipts issuer under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, share options, and confirmations related to share issuance and compliance with listing rules. The document is titled as a monthly report and contains detailed share issuance and share capital changes data for the month ending July 31, 2023. It is not an announcement of a report publication but the report itself. The content aligns with a Share Issue/Capital Change report, as it focuses on share capital and issuance changes, share options exercised, and confirmations of compliance with listing requirements. The document length is 4590 characters, which is sufficient for a detailed monthly share capital movement report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2023-08-04 Chinese
美股公告：季度报告10-Q表格
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) for the quarterly period ending June 30, 2023. It contains detailed unaudited interim consolidated financial statements, including balance sheets, income statements, cash flow statements, and notes to the financial statements. The document references compliance with the Securities Exchange Act of 1934 and includes management's discussion and analysis, risk factors, and other disclosures typical of a quarterly report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the actual quarterly report, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q2 2023
2023-08-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.